You are here: Industry Insights > PharmaCyte Biotech

News List

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules firstwordpharma
August 24, 2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules, of 14,000,000 shares of the Company's common stock
PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer pharmaceutical-business-review
September 08, 2020
PharmaCyte Biotech has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study biospace
April 18, 2018
PharmaCyte Biotech, Inc.today announced that it has successfully completed a “multiple course ifosfamide study” required by the U.S. Food and Drug Administration (FDA).